Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
The present invention relates to novel indole and benzoxazine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds and to the use of such compounds and compositions for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
1. A compound of Formula (I)
or a stereochemically isomeric form thereof, wherein
R 1 is C 1-6 alkyl; C 3-7 cycloalkyl; trifluoromethyl; C 1-3 alkyl substituted with trifluoromethyl, 2,2,2-trifluoroethoxy, C 3-7 cycloalkyl, phenyl, or phenyl substituted with halo, trifluoromethyl, or trifluoromethoxy; phenyl; phenyl substituted with 1 or 2 substituents selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy; or 4-tetrahydropyranyl;
R 2 is cyano, halo, trifluoromethyl, C 1-3 alkyl or cyclopropyl;
R 3 is hydrogen; C 1-3 alkyl; C 1-3 alkyl substituted with C 3-7 cycloalkyl, phenyl, phenyl substituted with 1 or 2 substituents selected from the group consisting of halo, cyano, C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl; hydroxyC 2-4 alkyl; C 1-3 alkyloxyC 2-4 alkyl; 4-tetrahydropyranyl; 1-oxa-spiro[3,5]non-7-yl; 2-oxa-spiro[3,5]non-7-yl; 1-oxa-spiro[4,5]dec-8-yl; 2-oxa-spiro[4,5]dec-8-yl; 4-(hydroxy)-cyclohexanyl; 4-(hydroxy)-4-(C 1-3 alkyl)cyclohexanyl; 4-(hydroxy)-4-(C 3-7 cycloalkyl)-cyclohexanyl; 4-(C 1-3 alkyloxy)cyclohexanyl; phenyl; pyridinyl; pyridinylmethyl; or phenyl, pyridinyl or pyridinylmethyl substituted with one or two substituents selected from the group consisting of halo, C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl;
R 4 is hydrogen or halo;
A is a radical of formula
—CH═CH— (a), or
—CH 2 —CH 2 —O— (b);
wherein one or two hydrogen atoms may be replaced by C 1-3 alkyl or polyhaloC 1-3 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of formula (I) according to claim 1 , wherein
R 1 is C 1-6 alkyl; C 1-3 alkyl substituted with trifluoromethyl or C 3-7 cycloalkyl;
R 2 is cyano or halo;
R 3 is hydrogen; C 1-3 alkyl; C 1-3 alkyl substituted with C 3-7 cycloalkyl; hydroxyC 2-4 alkyl; C 1-3 alkyloxyC 2-4 alkyl; 4-tetrahydropyranyl; 4-(hydroxy)-cyclohexanyl; or 4-(hydroxy)-4-(C 1-3 alkyl)cyclohexanyl;
R 4 is hydrogen, chloro or fluoro;
A is a radical of formula
—CH═CH— (a), or
—CH 2 —CH 2 —O— (b);
or a pharmaceutically acceptable salt thereof.
3. The compound of formula (I) according to claim 1 , wherein
R 1 is C 1-3 alkyl substituted with trifluoromethyl;
R 2 is cyano or chloro;
R 3 is hydrogen; methyl; methyl substituted with cyclopropyl; 2-hydroxy-2,2-dimethylethyl; 1-methylethyloxyethyl; 4-tetrahydropyranyl; 4-(hydroxy)-cyclohexanyl; or 4-(hydroxy)-4-(methyl)cyclohexanyl;
R 4 is hydrogen or chloro;
A is a radical of formula
—CH═CH— (a), or
—CH 2 —CH 2 —O— (b);
or a pharmaceutically acceptable salt thereof.
4. The compound of formula (I) according to claim 1 , wherein
R 1 is 2,2,2-trifluoroethyl;
R 2 is cyano or chloro;
A is a radical of formula —CH═CH— (a);
or a pharmaceutically acceptable salt thereof.
5. The compound of formula (I) according to claim 1 , wherein
R 1 is 2,2,2-trifluoroethyl;
R 2 is cyano or chloro;
A is a radical of formula —CH 2 —CH 2 -O— (b);
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
7. A method of treating, ameliorating, or controlling a central nervous system disorder in a human, comprising administering to the human in need thereof an effective amount of a compound according to claim 1 , wherein the central nervous system disorder is selected from the group consisting of anxiety disorders, psychotic disorders selected from the group consisting of schizophrenia , schizoaffective disorder and schizophreniform disorder, mood disorders, epilepsy or convulsive disorders, and dementia of the Alzheimer's type.
8. The method according to claim 7 , wherein the central nervous system disorder is an anxiety disorder, selected from the group consisting of agoraphobia, generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), social phobia and other phobias.
9. The method to claim 7 , wherein the central nervous system disorder is a psychotic disorder selected from the group consisting of schizophrenia, schizoaffective disorder, and schizophreniform disorder.
10. The method according to claim 7 , wherein the central nervous system disorder is a mood disorder selected from the group consisting of bipolar disorders (I & II), cyclothymic disorder, depression, dysthymic disorder, major depressive disorder and substance-induced mood disorder.
11. The method according to claim 7 , wherein the central nervous system disorder is epilepsy or a convulsive disorder selected from the group consisting of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness, infantile spasms, and epilepsy partialis continua, and other forms of epilepsy.